Porphobilinogen    (DrugBank: Porphobilinogen)

1 disease
IDDisease name (Link within this page)Number of trials
254Porphyria1

254. Porphyria    [ 59 clinical trials,   52 drugs,   (DrugBank: 17 drugs),   17 drug target genes,   33 drug target pathways]
Searched query = "Porphyria", "CEP", "Erythropoietic protoporphyria", "EPP", "X-linked dominant protoporphyria", "XLDP", "PCT", "HEP", "AIP", "ADP", "VP", "Hereditary coproporphyria", "HCP"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 59 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00418795
(ClinicalTrials.gov)
June 11, 20034/1/2007Porphozym in the Treatment of Acute Attacks in AIPA Multi-centre, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial, Investigating the Efficacy and Safety of Porphozym (Recombinant Human Porphobilinogen Deaminase) in the Treatment of Acute Attacks in AIPAcute Intermittent PorphyriaDrug: recombinant human porphobilinogen deaminase (Porphozym)Zymenex A/SNULLCompleted18 YearsN/AAll36Phase 2;Phase 3United States